期刊
JOURNAL OF CLINICAL LIPIDOLOGY
卷 5, 期 5, 页码 338-367出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2011.07.005
关键词
C-reactive protein; Lipoprotein-associated phospholipase A2; Apolipoprotein B; Low-density lipoprotein particle concentration; Lipoprotein(a); Lipoprotein subfractions
资金
- Abbott Laboratories
- Atherotech Diagnostics Laboratory
- Berkley Heart Lab, Inc.
- Boston Heart Diagnostics
- diaDexus, Inc.
- LipoScience
- Merck Co., Inc.
- Spectracell Laboratories
- Daiichi Sankyo
- GlaxoSmithKline
- Merck Co.
- Roche
- Aegerion Pharmaceuticals
- Amgen
- AstraZeneca
- Atherotech Inc.
- DTC MD
- Esperion
- Intelligent Medical Decisions
- Kinemed
- Novo Nordisk
- Sanofi-Aventis
- Synarc
- Takeda Pharmaceuticals
- Vindico Medical Education
- Bristol-Myers Squibb
- Kowa Pharmaceuticals
- Novartis Pharmaceuticals
- Sanofi-Synthelabo
- Adnexus
- Amylin Pharmaceuticals
- Bristol Myers-Squibb
- Genentech
- Idera Pharmaceuticals
- Omthera
- Resverlogix
- Amarin Pharmaceuticals
- National Institutes of Health
- Spirocor
- Gilead
- Pfizer Inc.
- Anthera
- Genzyme
- Isis Pharmaceuticals
- LabCorp
- Health Diagnostics Laboratory
- Alpha-Core Pharmaceuticals
- VirxSys Inc.
- ISIS
- Genzyme/Sanofi
- Quest
- Atherotech
- Bio-Sante Pharmaceuticals
- Cargill
- Coca-Cola
- Dairy Research Institute
- Fermenich
- Kao Corporation
- Kellogg Co.
- Monsanto
- National Starch/Corn Products
- Ocean Spray
- PepsiCo
- Pharmavite
- Shaklee
- Solae
- Trygg Pharmaceuticals
- Welch's
- General Mills
- Biofortis
The National Cholesterol Education Program Adult Treatment Panel guidelines have established low-density lipoprotein cholesterol (LDL-C) treatment goals, and secondary non-high-density lipoprotein (HDL)-C treatment goals for persons with hypertriglyceridemia. The use of lipid-lowering therapies, particularly statins, to achieve these goals has reduced cardiovascular disease (CVD) morbidity and mortality; however, significant residual risk for events remains. This, combined with the rising prevalence of obesity, which has shifted the risk profile of the population toward patients in whom LDL-C is less predictive of CVD events (metabolic syndrome, low HDL-C, elevated triglycerides), has increased interest in the clinical use of inflammatory and lipid biomarker assessments. Furthermore, the cost effectiveness of pharmacological intervention for both the initiation of therapy and the intensification of therapy has been enhanced by the availability of a variety of generic statins. This report describes the consensus view of an expert panel convened by the National Lipid Association to evaluate the use of selected biomarkers [C-reactive protein, lipoprotein-associated phospholipase A(2), apolipoprotein B, LDL particle concentration, lipoprotein(a), and LDL and HDL subfractions] to improve risk assessment, or to adjust therapy. These panel recommendations are intended to provide practical advice to clinicians who wrestle with the challenges of identifying the patients who are most likely to benefit from therapy, or intensification of therapy, to provide the optimum protection from CV risk. (C) 2011 National Lipid Association. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据